Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Eve vs ShedRx

By GLP-1 ScorecardUpdated

Eve
Site position #212

Lower grade

ShedRx
Site position #3

Higher grade

Score comparison

ShedRx has the higher recorded score — 87/100 to 66.3/100.

ShedRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Shed combines compounded injections and branded Wegovy/Zepbound options with coaching; compare longer-plan supply, fees and guarantee rules before committing.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueShedRx +29
55
84
Dose & formulationShedRx +8
88
96
Clinical oversightShedRx +5
79
84
Labs & monitoringShedRx +32
52
84
FulfillmentShedRx +21
67
88
Contract termsShedRx +44
41
85
Eve · top barShedRx · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricEveShedRx
WeighScore66.3/10087/100
GradeCB+
Site position#212#3
Semaglutide$195/mo (compounded)$199/mo
Tirzepatide$195/mo (compounded)$299/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessYesYes
Oral / sublingualYesYes
Eve

Site position #212 · C

Strengths

  • Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
  • Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
  • Publishes the FDA compounded-medication disclaimer
  • Oral sublingual semaglutide offered alongside injectable

What to consider

  • Full states-served list not disclosed publicly
  • 503A pharmacy partner not named, and 503A vs 503B status not specified
  • Named medical director / clinical leadership not disclosed
  • Corporate legal entity not disclosed
  • Governing law / arbitration venue not stated
ShedRx

Site position #3 · B+

Strengths

  • Published injection plans plus other formulation and branded prescribing options
  • One-month injection prices listed at $199 semaglutide / $299 tirzepatide
  • Terms describe monthly coaching and name six possible pharmacy partners

What to consider

  • Six- and twelve-month plans specify 24 and 48 weeks of medication
  • The 120-day promise has first-time-user and participation requirements and does not cancel a longer plan
  • Branded pages display conflicting $99/$125 membership charges, with medication separate
  • Actual clinician/pharmacy assignment and the applicable minimum term need confirmation

Featured provider

ShedRx

ShedRx scores 87/100 (B+). Shed combines compounded injections and branded Wegovy/Zepbound options with coaching; compare longer-plan supply, fees and guarantee rules before committing.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard